Tokyo, September 18, 2020: Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative…
Tokyo, July 17, 2019: Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate)…